ACIP Reports on First “Do-It-Yourself at Home” Nasal Flu Shot
In September 2024, the U.S. Food and Drug Administration (FDA) licensed the first of its kind live attenuated nasal spray influenza vaccine to be administered at home during the 2024-2025 “flu season.” Adults up to the 49 years of age are eligible to self-administer the FluMist Home vaccine or give it to their children aged […]
CDC’s ACIP Forms Workgroup to Back New Lyme Disease Vaccine and Monoclonal Antibody Products
At an Apr.15-16, 2025 meeting of the U.S. Centers for Disease and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), it was announced that a workgroup had been formed to further development of a new vaccine for Lyme disease. The first session of the new group will take place in May with a presentation scheduled […]
HHS Halts Funding for Development of Next-Generation COVID Biologics
The U.S. Department of Health and Human Services (DHHS) has stopped U.S. government funding for the development of next-generation COVID-19 biologics by two companies, GeoVax, Inc. of Atlanta, Georgia and CastleVax, Inc. of New York. The project had been funded by Project NextGen, a Biden administration initiative under the U.S. Center for the Biomedical Advanced […]
Guillain-Barré Syndrome Warning Added to Shingrix Vaccine in Australia
In February 2024, Australia’s Therapeutic Goods Administration (TGA), the country’s national regulatory authority for drugs and, initiated an investigation into a potential association between GSK plc’s Shingrix shingles vaccine, Guillain-Barré syndrome (GBS), which causes inflammation and damage to the nerves, that may include paralysis.1 The investigation was prompted by two reports of GBS following Shingrix […]
U.S. Government Accused of Hiding Deadly E. Coli Outbreak
A deadly E. coli outbreak reportedly linked to food was kept hidden by the U.S. government health agencies according to a new lawsuit. The California legal case alleges that a November 2024 E. coli outbreak sickened 89 people in 15 states.1 One person died while 36 others were hospitalized, including a nine-year-old boy who suffered […]
Pfizer Ends Development of Weight-Loss Pill After Liver Injury in Trial Participant
Pfizer, Inc. announced that it is discontinuing development of its experimental daily weight loss pill after a trial participant suffered a liver injury potentially linked to the drug. The company confirmed that the oral GLP-1 drug, danuglipron (PF-06882961), is no longer in development following the incident.1 Pfizer has been studying danuglipron since 2022.2 A Pfizer […]